文献速递淋巴瘤

英国NCRI研究:初治晚期滤泡性淋巴瘤CMD与FMD方案比较及分子学缓解对总生存的预测

The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival.
PubMed 文献 · Br J Haematol · 2020-03-09

英国NCRI长期随访研究纳入400例初治晚期症状性滤泡性淋巴瘤患者,比较CMD与FMD方案,两组PFS和OS无显著差异;分子学阴性患者PFS和OS显著优于阳性患者,且随访6年后MRD阴性者无进展。

要点

  • CMD与FMD方案在初治晚期FL中PFS和OS无显著差异。
  • 分子学缓解率两组相似,但分子学阴性显著改善PFS和OS。
  • 随访6年后MRD阴性患者无进展,支持MRD指导预后。

核心结论

  • CMD与FMD方案在初治晚期症状性FL中疗效相当,但分子学缓解可显著预测延长总生存。

研究设计与样本

  • 英国NCRI前瞻性研究,纳入400例初治晚期症状性滤泡性淋巴瘤患者,比较CMD与FMD方案并评估分子学缓解。

主要发现

  • 随访6年后MRD阴性患者无进展病例。

临床怎么用

  • 分子学缓解(MRD阴性)可用于初治晚期FL的预后分层,指导后续治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We present a long-term follow-up of the UK chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced, symptomatic follicular lymphoma (FL). This trial was the first to prospectively assess molecular response and the impact on outcomes for 400 patients. The median progression-free survival (PFS) and overall survival (OS) for CMD were 3·6 and 14·6 years vs. 3·0 and 15·7 years for FMD, respectively. Estimates for Restricted Mean Survival Time (RMST) suggested no difference in PFS or OS. For the whole cohort there was a highly significant difference in survival by POD24, with a median OS from a risk-defining event of 3·9 years compared to 13·7 years for all others (RMST P < 0·001). Molecular remission was achieved in 25/46 patients (54·3%) in the CMD arm and 20/41 (48·8%) in the FMD arm (P = 0·6). Molecular negativity resulted in median PFS of 5·6 years vs. 2·3 years for molecularly positive (log-rank P < 0·001) and median OS not reached versus 12·5 years (log-rank P < 0·01). No cases of progression occurred in minimal residual disease (MRD) negative patients after six years of follow-up. Although there was no difference in outcomes between arms, this is the first prospective study to report MRD negativity resulting in significantly improved OS.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Bishton MJ, Rule S, Wilson W, et al. The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival. Br J Haematol. 2020. PMID: 32150649. doi:10.1111/bjh.16555

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。